ImmuCell Corporation (ICCC) vs Milestone Pharmaceuticals Inc. (MIST)
A side-by-side comparison of ImmuCell Corporation and Milestone Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ICCC
ImmuCell Corporation
$9.85HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT
MIST
Milestone Pharmaceuticals Inc.
$0.79HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
Total return — ICCC vs MIST
growth of $100 · dividends reinvested · last 7yICCC +64.4% (+7.4%/yr)MIST -94.9% (-34.7%/yr)ICCC compounded faster over this window
Log scale — wide-divergence pair
ICCC MIST
ICCC vs MIST: by the numbers
- •MIST is the larger company ($98M vs $89M market cap).
- •ICCC is profitable (2.57% net margin) while MIST runs a net loss (-3585.62%).
- •ICCC grew revenue faster over the past five years (13.74% vs -31.02% CAGR).
Metrics side by side
Valuation
| Metric | ICCC | MIST |
|---|---|---|
| P/E ratio | 116.43 | N/A |
| P/S ratio | 2.90 | 41.74 |
| P/B ratio | 2.84 | 5.37 |
| EV / EBITDA | 14.83 | N/A |
| FCF yield | 4.73% | N/A |
Profitability
| Metric | ICCC | MIST |
|---|---|---|
| Gross margin | 40.32% | 94.58% |
| Operating margin | 12.60% | -4041.72% |
| Net margin | 2.57% | -3585.62% |
| ROE | 2.51% | -461.14% |
| ROIC | 8.16% | -49.27% |
Growth (annualized)
| Metric | ICCC | MIST |
|---|---|---|
| Revenue CAGR (5Y) | 13.74% | -31.02% |
| Total return CAGR (5Y) | 0.65% | -33.18% |
Frequently asked
- Which has grown faster, ICCC or MIST?
- Over the past five years, ICCC grew revenue faster — ICCC at a 13.74% CAGR versus MIST at -31.02%.
- Is ICCC or MIST more profitable?
- ICCC runs the higher net margin — ICCC at 2.57% versus MIST at -3585.62%.
- How have ICCC and MIST total returns compared?
- Over the past 5 years, ICCC delivered 0.65% and MIST delivered -33.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ImmuCell P/E ratioImmuCell ROEMilestone Pharmaceuticals ROEImmuCell operating marginMilestone Pharmaceuticals operating marginImmuCell revenue growthMilestone Pharmaceuticals revenue growthImmuCell free cash flowMilestone Pharmaceuticals free cash flow
ImmuCell & Milestone Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.